Point72 Asset Management
NTLA icon

Point72 Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Point72 Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.46M Buy
+270,011
New +$3.44M ﹤0.01% 1946
2025
Q4 		– Sell
-174,261
Closed -$2.4M – 4086
2025
Q3 		$3.01M Buy
+174,261
New +$2.15M 0.01% 1275
2021
Q2 		– Sell
-180,400
Closed -$14.5M – 1106
2021
Q1 		$14.5M Buy
180,400
+34,900
+24% +$2.34M 0.07% 339
2020
Q4 		$7.92M Sell
145,500
-507,619
-78% -$18.4M 0.04% 493
2020
Q3 		$13M Sell
653,119
-217,788
-25% -$4.54M 0.07% 353
2020
Q2 		$18.3M Buy
+870,907
New +$14.8M 0.12% 225

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management's NTLA Position: Q1 2026 in Review

Point72 Asset Management opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 270,011 shares worth $3.46M. The stake represents ﹤0.01% of the portfolio and ranks #1946 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in NTLA as recently as Q3 2025.

Point72 Asset Management first reported a position in NTLA in Q2 2020 and has held it in 6 quarters since. The position peaked at $18.3M in Q2 2020. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Point72 Asset Management held 270,011 shares of Intellia Therapeutics worth $3.46M as of Q1 2026.
  • Intellia Therapeutics was a new Point72 Asset Management position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1946 holding.
  • Point72 Asset Management first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • Point72 Asset Management's Intellia Therapeutics position peaked at $18.3M in Q2 2020.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.